{"id":"moxaverine","rwe":[{"pmid":"37554009","year":"2023","title":"Ru-catalyzed C-H activation/cyclization of oximes with sulfoxonium ylides to access isoquinolines.","finding":"","journal":"Organic & biomolecular chemistry","studyType":"Clinical Study"},{"pmid":"36349148","year":"2022","title":"Facile synthesis of isoquinolines and isoquinoline N-oxides via a copper-catalyzed intramolecular cyclization in water.","finding":"","journal":"RSC advances","studyType":"Clinical Study"},{"pmid":"28809458","year":"2017","title":"Redox-Neutral Manganese(I)-Catalyzed C-H Activation: Traceless Directing Group Enabled Regioselective Annulation.","finding":"","journal":"Angewandte Chemie (International ed. in English)","studyType":"Clinical Study"},{"pmid":"27273816","year":"2016","title":"Rh(iii)-catalyzed C-H activation/cyclization of oximes with alkenes for regioselective synthesis of isoquinolines.","finding":"","journal":"Organic & biomolecular chemistry","studyType":"Clinical Study"},{"pmid":"23971874","year":"2013","title":"Update on current and future novel therapies for dry age-related macular degeneration.","finding":"","journal":"Expert review of clinical pharmacology","studyType":"Clinical Study"}],"tags":[{"label":"moxaverine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"A03AD30","category":"atc"},{"label":"Active","category":"status"},{"label":"Parasympatholytics","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"eupaverin","offLabel":[],"synonyms":["moxaverine","eupaverin"],"timeline":[],"approvals":[],"brandName":"Eupaverin","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"moxaverine","explanation":"Imagine your body's physiological processes as a complex orchestra. Eupaverin is like a conductor that helps the different instruments work together in harmony. By modulating these processes, it can help restore balance and alleviate symptoms.","oneSentence":"Eupaverin works by interacting with specific biological pathways to produce its effects.","technicalDetail":"Eupaverin's exact mechanism of action is unknown, but it is believed to involve interactions with various ion channels and receptors, potentially influencing neurotransmitter release and synaptic plasticity."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1853","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MOXAVERINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MOXAVERINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:51:14.606223","biosimilars":[],"competitors":[{"drugName":"papaverine","drugSlug":"papaverine","fdaApproval":"","relationship":"same-class"}],"genericName":"moxaverine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"papaverine","brandName":"papaverine","genericName":"papaverine","approvalYear":"","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01629680","phase":"PHASE2","title":"A Randomized, Placebo-controlled Study Investigating the Effects of Moxaverine on Ocular Blood Flow After Oral Administration in Healthy Subjects","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2010-10","conditions":["Effect of Orally Administrated Moxaverine on Ocular Blood Flow"],"enrollment":16,"completionDate":"2011-06"},{"nctId":"NCT00709449","phase":"PHASE2,PHASE3","title":"An Open Study Comparing the Effects of Moxaverine on Ocular Blood Flow in Patients With Age- Related Macular Degeneration, Primary Open Angle Glaucoma and Healthy Control Subjects","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2008-05","conditions":["Macular Degeneration","Glaucoma","Regional Blood Flow"],"enrollment":60,"completionDate":"2009-03"},{"nctId":"NCT00709423","phase":"PHASE2","title":"Effects of Moxaverine and Placebo on Ocular Blood Flow","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2007-03","conditions":["Regional Blood Flow","Ocular Physiology","Retina"],"enrollment":16,"completionDate":"2007-05"},{"nctId":"NCT00569621","phase":"PHASE2","title":"A Randomized, Double-Masked, Placebo-Controlled Two Cross Over Study Comparing the Effects of Moxaverine and Placebo on Ocular Blood Flow","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2007-03","conditions":["Ischemia"],"enrollment":16,"completionDate":"2007-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"006568","UNII":"P3P08Y1XJ4","CHEBI":"CHEBI:135307","INN_ID":"4005","RXNORM":"52918","UMLSCUI":"C0129044","ChEMBL_ID":"CHEMBL2105060","KEGG_DRUG":"D07089","DRUGBANK_ID":"DB12251","PUBCHEM_CID":"70882","MESH_SUPPLEMENTAL_RECORD_UI":"C004490"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":18,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"A03AD30","allCodes":["A03AD30"]},"biosimilarFilings":[],"recentPublications":[{"date":"2023 Aug 23","pmid":"37554009","title":"Ru-catalyzed C-H activation/cyclization of oximes with sulfoxonium ylides to access isoquinolines.","journal":"Organic & biomolecular chemistry"},{"date":"2022 Oct 24","pmid":"36349148","title":"Facile synthesis of isoquinolines and isoquinoline N-oxides via a copper-catalyzed intramolecular cyclization in water.","journal":"RSC advances"},{"date":"2017 Oct 2","pmid":"28809458","title":"Redox-Neutral Manganese(I)-Catalyzed C-H Activation: Traceless Directing Group Enabled Regioselective Annulation.","journal":"Angewandte Chemie (International ed. in English)"},{"date":"2016 Jul 14","pmid":"27273816","title":"Rh(iii)-catalyzed C-H activation/cyclization of oximes with alkenes for regioselective synthesis of isoquinolines.","journal":"Organic & biomolecular chemistry"},{"date":"2013 Sep","pmid":"23971874","title":"Update on current and future novel therapies for dry age-related macular degeneration.","journal":"Expert review of clinical pharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eupaverin is a small molecule with the synonyms MOXAVERINA, MOXAVERINE, MOXAVERINE, and MOXAVERINE. It has been studied in clinical trials for conditions such as macular degeneration, glaucoma, and ischemia, with interventions including moxaverine and placebo.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}